Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045277 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT02045277: Completed Phase 2 study, sponsored by Bausch Health Americas.
NCT02045277 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 212 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02045277, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety and efficacy of a topical lotion
Primary Outcome
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe).
Interventions
- DRUG IDP-118 Lotion
- DRUG IDP-118 Vehicle Lotion
- DRUG IDP-118 Monad HP Lotion
- DRUG IDP-118 Monad Taz Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT02045277 record still lists
NCT02045277 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher).
The record links to 0 conditions, and to 4 interventions - of which IDP-118 Lotion is the first listed.
NCT02045277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02045277 about?
NCT02045277 is a clinical study titled "Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis". The objective of the study is to evaluate the safety and efficacy of a topical lotion
What is the current status of trial NCT02045277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2014-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02045277?
The interventions under investigation include: IDP-118 Lotion (DRUG), IDP-118 Vehicle Lotion (DRUG), IDP-118 Monad HP Lotion (DRUG), IDP-118 Monad Taz Lotion (DRUG).
Who is sponsoring clinical trial NCT02045277?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02045277's enrollment target sits among peer trials
212 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia